UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000022727
Receipt number R000026178
Scientific Title Investigation of method for prediction of therapeutic effect of adalimumab initial therapy for inflammatory bowel disease
Date of disclosure of the study information 2016/06/14
Last modified on 2016/06/13 23:07:57

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Investigation of method for prediction of therapeutic effect of adalimumab initial therapy for inflammatory bowel disease

Acronym

IPADIN study

Scientific Title

Investigation of method for prediction of therapeutic effect of adalimumab initial therapy for inflammatory bowel disease

Scientific Title:Acronym

IPADIN study

Region

Japan


Condition

Condition

Ulcerative colitis, Crohn's disease

Classification by specialty

Gastroenterology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

We have investigated whether trough level of Adalimumab predicts future outcomes of induction therapy.

Basic objectives2

PK,PD

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

The primary end point was prediction of a clinical response at 6 months.

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

13 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Patients with IBD who admitted to ofuna chuo hospital for induction therapy of Adalimumab.

Patients who gave written informed consent for this study

Key exclusion criteria

Patients who are considered not suitable for Adalimumab use due to contraindication or considerable risks such as hypersensitivity to Adalimumab.

Other than above mentioned criteria, patients who are judged inappropriate by the doctor.

Target sample size

20


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Atsushi Yoshida

Organization

Ofuna Chuo Hospital

Division name

Center for Gastroenterology and Inflammatory Bowel Disease

Zip code


Address

Ofuna 6-2-24, Kamakura, Japan

TEL

+81-46-745-2111

Email

atushi.y@kza.biglobe.ne.jp


Public contact

Name of contact person

1st name
Middle name
Last name Atsushi Yoshida

Organization

Ofuna Chuo Hospital

Division name

Center for Gastroenterology and Inflammatory Bowel Disease

Zip code


Address

Ofuna 6-2-24, Kamakura, Japan

TEL

+81-46-745-2111

Homepage URL


Email

atushi.y@kza.biglobe.ne.jp


Sponsor or person

Institute

Ofuna Chuo Hospital

Institute

Department

Personal name



Funding Source

Organization

none

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2016 Year 06 Month 14 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Date of protocol fixation

2016 Year 04 Month 04 Day

Date of IRB


Anticipated trial start date

2016 Year 04 Month 04 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

We have investigated whether trough level of Adalimumab predicts future outcomes of induction therapy using PK/PD model.


Management information

Registered date

2016 Year 06 Month 13 Day

Last modified on

2016 Year 06 Month 13 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000026178


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name